CAGRISEMA 10 mg
$90.00
Dual amylin/GLP-1 co-formulation for multi-pathway metabolic research. ≥98% purity, 10 mg lyophilized. For laboratory research only.
- 🔒 Secure Checkout
- ↩️ 30-Day Easy Returns
- ⭐ Premium Quality Guaranteed
🛍️ Frequently Bought Together
🔒Secure Checkout
🚚Fast Shipping
↩️Easy Returns
✅Quality Guaranteed
Description
CagriSema is an investigational fixed-ratio co-formulation combining Cagrilintide (a long-acting amylin analog) with Semaglutide (a GLP-1 receptor agonist).
Research Profile
This dual-mechanism research compound leverages the complementary anorexigenic pathways of amylin and GLP-1 receptor signaling. Phase III clinical trials have explored the additive effects of area postrema-mediated satiety (via amylin receptors) combined with hypothalamic and vagal GLP-1R engagement, representing a novel paradigm in multi-pathway metabolic research.
Amylin + GLP-1 CombinationDual-Pathway10 mg Lyophilized≥98% Purity
This product is not a drug, dietary supplement, or food. It is not intended to diagnose, treat, cure, or prevent any disease. No claims are made regarding biological activity, outcomes, or effects. By purchasing this product, the buyer acknowledges that it is for research use only and agrees to handle, store, and dispose of it in accordance with all applicable laws and regulations.




Reviews
There are no reviews yet.